Mark Kong CFA
Stock Analyst at DBS
(1.84)
# 3,425
Out of 5,125 analysts
33
Total ratings
45.5%
Success rate
0.6%
Average return
Main Sectors:
Stocks Rated by Mark Kong CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HKG: 9969 InnoCare Pharma Limited | Reiterated: Buy | $18.30 | $11.90 | +53.78% | 2 | Nov 9, 2026 | |
| HKG: 3692 Hansoh Pharmaceutical Group Company Limited | Initiated Coverage: Buy | $46.00 | $34.36 | +33.88% | 1 | Oct 30, 2026 | |
| HKG: 6160 BeOne Medicines AG | Reiterated: Buy | $290.00 | $251.80 | +15.17% | 5 | Sep 28, 2026 | |
| HKG: 1681 Consun Pharmaceutical Group Limited | Reiterated: Buy | $26.00 | $16.02 | +62.30% | 6 | Sep 17, 2026 | |
| HKG: 1801 Innovent Biologics, Inc. | Reiterated: Buy | $144.00 | $86.80 | +65.90% | 3 | Sep 15, 2026 | |
| HKG: 1093 CSPC Pharmaceutical Group Limited | Initiated Coverage: Buy | $13.70 | $8.53 | +60.61% | 1 | Sep 10, 2026 | |
| HKG: 1177 Sino Biopharmaceutical Limited | Initiated Coverage: Buy | $6.50 | $5.54 | +17.43% | 1 | May 20, 2026 | |
| HKG: 2105 Laekna, Inc. | Reiterated: Buy | $24.16 | $6.60 | +266.06% | 6 | Mar 20, 2026 | |
| HKG: 1099 Sinopharm Group Co. Ltd. | Upgraded: Buy | $25.00 | $16.76 | n/a | 1 | Dec 12, 2024 | |
| HKG: 1515 China Resources Medical Holdings Company Limited | Reiterated: Buy | $7.50 | $2.58 | n/a | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $48.23 | n/a | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $547.89 | n/a | 2 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $293.89 | n/a | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $250.83 | n/a | 1 | Sep 13, 2024 |
InnoCare Pharma Limited
Nov 9, 2026
Reiterated: Buy
Price Target: $18.30
Current: $11.90
Upside: +53.78%
Hansoh Pharmaceutical Group Company Limited
Oct 30, 2026
Initiated Coverage: Buy
Price Target: $46.00
Current: $34.36
Upside: +33.88%
BeOne Medicines AG
Sep 28, 2026
Reiterated: Buy
Price Target: $290.00
Current: $251.80
Upside: +15.17%
Consun Pharmaceutical Group Limited
Sep 17, 2026
Reiterated: Buy
Price Target: $26.00
Current: $16.02
Upside: +62.30%
Innovent Biologics, Inc.
Sep 15, 2026
Reiterated: Buy
Price Target: $144.00
Current: $86.80
Upside: +65.90%
CSPC Pharmaceutical Group Limited
Sep 10, 2026
Initiated Coverage: Buy
Price Target: $13.70
Current: $8.53
Upside: +60.61%
Sino Biopharmaceutical Limited
May 20, 2026
Initiated Coverage: Buy
Price Target: $6.50
Current: $5.54
Upside: +17.43%
Laekna, Inc.
Mar 20, 2026
Reiterated: Buy
Price Target: $24.16
Current: $6.60
Upside: +266.06%
Sinopharm Group Co. Ltd.
Dec 12, 2024
Upgraded: Buy
Price Target: $25.00
Current: $16.76
Upside: n/a
China Resources Medical Holdings Company Limited
Oct 24, 2024
Reiterated: Buy
Price Target: $7.50
Current: $2.58
Upside: n/a
Oct 11, 2024
Reiterated: Buy
Price Target: n/a
Current: $48.23
Upside: n/a
Oct 8, 2024
Reiterated: Hold
Price Target: n/a
Current: $547.89
Upside: n/a
Sep 13, 2024
Reiterated: Hold
Price Target: n/a
Current: $293.89
Upside: n/a
Sep 13, 2024
Reiterated: Buy
Price Target: n/a
Current: $250.83
Upside: n/a